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Abstract
In drug discovery, the characterisation of the precise modes of action (MoA) and of unwanted off-target effects of novel
molecularly targeted compounds is of highest relevance. Recent approaches for identification of MoA have employed
various techniques for modeling of well defined signaling pathways including structural information, changes in phenotypic
behavior of cells and gene expression patterns after drug treatment. However, efficient approaches focusing on proteome
wide data for the identification of MoA including interference with mutations are underrepresented. As mutations are key
drivers of drug resistance in molecularly targeted tumor therapies, efficient analysis and modeling of downstream effects of
mutations on drug MoA is a key to efficient development of improved targeted anti-cancer drugs. Here we present a
combination of a global proteome analysis, reengineering of network models and integration of apoptosis data used to
infer the mode-of-action of various tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) cell lines expressing
wild type as well as TKI resistance conferring mutants of BCR-ABL. The inferred network models provide a tool to predict the
main MoA of drugs as well as to grouping of drugs with known similar kinase inhibitory activity patterns in comparison to
drugs with an additional MoA. We believe that our direct network reconstruction approach, demonstrated on proteomics
data, can provide a complementary method to the established network reconstruction approaches for the preclinical
modeling of the MoA of various types of targeted drugs in cancer treatment. Hence it may contribute to the more precise
prediction of clinically relevant on- and off-target effects of TKIs.
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Introduction
Tyrosine kinase inhibitors (TKIs) are nowadays frequently used
for treatment of defined solid and hematological cancer entities.
Although these drugs are typically developed for the targeting of
single kinases which are specifically overexpressed in cancer cells
[1,2,3], in reality they usually inhibit a multitude of kinases and
nonkinase targets [4,5,6,7] resulting in a heterogeneous activity
profile which is poorly predictable. Based on this off-target activity
most of the clinically used TKIs exert relevant side effects which
can interfere with the efficacy of the treatment regime [8,9,10]
leading to unfavorable therapeutic windows. Therefore, the
prediction of drug action profile as early as possible in the drug
research and discovery process is of eminent importance to avoid
clinical trials using compounds with unforeseen unfavorable
efficacy – risk profiles. The realization of the ‘‘fail early principle’’,
however, requires methods to extract drug action from drug
response profiles based on high throughput testing in well defined
cell culture systems. Moreover, identification of the full set of
modes-of-action (MoA) of drugs and the assessment of their
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respective impact on secondary drug action are of utmost
importance both for optimal selection of targets or alternatively,
combinations of targets for optimization of future drug discovery
as well as for the optimal administration of already existing
compounds. Due to the molecular complexity of the various
cancer entities, network reconstruction of MoA from combinato-
rial drug experimentation will be of special relevance for cancer
therapies [11]. Several methods for identification of MoA, side
effects and drug efficacy from cellular drug responses have been
described. Prediction of drug efficacy as well as potential adverse
side effects can be performed by chemical structures and
experimental data from cell screening experiments of the
compounds using appropriate similarity scores [12,13,14,15,16].
An alternative approach uses established network information with
respect to known MoA’s and predicts side effects identified by
cooperative pathway analysis [17]. Experimentally derived dose-
response surfaces from combinatorial drug experiments can be
used to identify simplified or detailed models for the respective
MoA’s and their interactions from analysis of the combinatorial
drug response surfaces [18,19,20]. The reconstruction is per-
formed by a systematic fit of models for drug action to the dose-
response surfaces, whereas the underlying models can show a
widely varying degree of detail. The models can be based on the
simplified concepts of Loewe additivity and Bliss independence
and go up to mechanistic systems biology models, where the
respective pathways involved in the MoA are represented in detail
and have to be fit to the data. However, due to the lack of data and
detailed understanding of the MoA, model fitting from dose-
response surfaces may become ill-posed when the grade of details
represented by the model is increased. Hence, model-fitting
approaches tend to result in ambiguous network reconstructions
when the size of the networks becomes large. The ill-posedness can
be reduced by reduction of complexity either by shrinking the
models to simplified network topology or by reducing the
interaction between involved pathways to simplified mechanisms,
such as boolean networks. In any case there will be payoffs by
loosing biological features which are specific to the model. Hence,
most applications tend to analyse the data using a set of models
and decide according to a ranking of the respective model
accuracies. A more generic drawback of fitting models to drug-
response surfaces arises when the MoA’s are not fully understood.
Then the inherent issue arises that the model structure does not
represent the biological mechanisms, which can lead to systematic
errors in network reconstruction and model predictivity. Another
approach to overcome the ill-posedness of models derived from
combinatorial drug-response surfaces may be a systematic
integration of multiple outputs of drug action into a network
integrating drug descriptors, MoA and pharmacological data [21].
Whereas the abovementioned approaches focus on specific
pharmacological applications, combinatorial network reconstruc-
tion has been used to reconstruct generic signaling networks as
well. Most of these approaches are based on evaluation of drug
treatment on gene expression or protein phosphorylation profiles
and the subsequent development of algorithms for reengineering
of signaling networks [22,23]. Combinatorial optimization algo-
rithms are mostly being used in order to identify the relevant
signaling networks out of a given set of pathway proteins. In
principal, these networks have the potential to enable the
identification of direct and specific drug targets or preferentially
affected signaling pathways [24,25]. Recently efficient, systematic
and direct network reconstructions of induced phosphorylation of
signaling proteins have been reported using combined stimulation
and inhibition of cell cultures [26], where complex interaction
networks have been reconstructed in detail from data describing
combinatorial stimulation and inhibition of cells, using a highly
multi-variate readout (phosphorylation of signaling proteins).
Despite the tremendous improvement of understanding complex
signaling networks and the interaction of the relevant pathways,
drug effects mediated by yet unexpected cellular mechanisms,
potentially as a secondary response on the primary drug action,
may not sufficiently be assessed due to lacks in model structures.
Hence novel unsupervised network reconstruction algorithms
which are based on data obtained from broad-scale transcriptome
and/or proteome profiling are needed as complementary method.
In this paper we use a combinatorial network reengineering
approach which is based on data representing the combinatorial
effect of multiple input data (TKI’s and mutations) on multiple
output data (set of proteins responding on the combinations of
administered drugs and mutations).
The respective analysis is of very high relevance to targeted
therapies, where development and/or selection of mutations in the
targets or in the addressed pathways plays a major role in drug
resistance with high relevance for personalized therapeutic
approaches. In this case the drug-response surface is not
continuous, since the mutations (as a combinatorial input variable)
induce a discrete structure in the inputs, hampering the
application of fitting of models from drug-response surfaces.
Moreover, the screening was performed only for four drugs, which
are known to show specific action against the target, in one
concentration only, so the broad data set required for unsuper-
vised approaches was not available and models based on chemical
structures leading to the prediction of broad side effects will not be
specific enough. In addition, due to the unspecific targeting of
thyrosine kinases by TKI’s we aimed to assess the MoA on a
proteome-wide scale.
Because of the sparse data available, we used a direct network
reconstruction approach which is focused on the identification of
unknown network topologies on a simplified level of details [27].
Similar to the approach used in [17], the model describing the
mechanisms of interaction between the input variables (here drugs
and mutations) and the output variables (here induced protein
expression and apoptosis) is represented by an abstract network. In
contrast to network models representing the detailed mechanisms
(where the nodes may represent explicitly addressed proteins or
genes), our abstract network reconstruction identifies only
(abstract) pathways linking drugs and the readouts (here protein
expression and apoptosis), the overlap of the pathways as well as
the localization of the pathway disruption by mutations
(Figure 1A). The edges represent the induction of a biological
effect (either activation or inhibition) by the drug, whereas the
nodes represent junctions of the pathways or breakpoints where a
pathway can be interrupted by a mutation. For simplicity, the
breakpoints where a pathway can be interrupted by a mutation
can be represented by a node located on an edge, too (red bar).
Although the nodes in the abstract network model do not
represent well identified biological mechanisms, the model
provides an overview about the existence of multiple pathways
controlling the drug action as well as their mutual interactions and
interaction with mutations. As the model can be identified in an
unsupervised manner, it may provide a first stage towards more
detailed modeling helping to avoid a bias due to incomplete a
priori knowledge. Moreover, this concept allows a continuous
transition of model types in terms of the level of details, starting
from very black-box models ending up at fully mechanistic models
[28] and is established in modeling complex chemical processes
[29,30]. Because of the variable level of network details, we call
this type of models meso-scale networks. Recently it has been
shown, that the topology of such meso-scale networks can be
Meso Scale Networks and Drug Mode-of-Action
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reconstructed from data without fitting of models, even if almost
no restriction is assumed for the functional form of the nodes [27].
The drawback is that the method so far requires a feed-forward
structure which can be decomposed into tree structures, so no
feedback loops can be identified. Hence the method is mostly
restricted on network reconstruction on a rough level of details.
Although this approach does not directly specify the role of specific
biological mechanisms in drug response, it allows the assessment of
the number of pathways and their interaction providing hypothesis
for detailed mechanistic follow-up research. It thereby provides a
valuable approach which is complementary to the established
methods providing an unbiased assessment of mechanisms and
their interaction on a proteome-wide scale in a first level analysis.
Chronic myeloid leukemia (CML) represents an excellent model
disease for development of cancer-specific TKIs [31]. Currently,
three different TKIs, Imatinib (IM) [32], Nilotinib (NILO) [33]
and Dasatinib (DASA) [34], are approved for first and second line
treatment and novel drugs such as dual BCR-ABL/src inhibitor
Bosutinib [35,36,37], dual aurora/BCR-ABL inhibitor Danusertib
(DANU) [38] and multi targeted TKI Ponatinib are being
evaluated in clinical trials [39,40,41]. From clinical use and
experimental evidence it is known that the efficacy and side-effect
profile of individual TKIs depends on targeted MoA as well as on
indirect responses based on the unspecific inhibition of various
kinases [1].
In the current study, we aimed to develop a model approach for
the prediction of the MoA of TKIs reengineered from global
proteome data. We describe unraveling of meso scale networks
based on protein expression changes induced by four kinase
inhibitors (IM, DASA, NILO and DANU) in wild type BCR-ABL
positive cells as well as in mutants (i.e. BCR-ABL mutation
M351T and T315I) which confer different degrees of resistance to
the TKIs tested. Furthermore, we present a model for integration
of protein expression data and induction of apoptosis. In
conclusion, we present a promising novel approach which can
be used for prediction of multiple drug MoA in various clinical
settings. We show that screening of protein response on
combinatorial stimulation by drugs as well as inhibition by
mutations can be used for the delineation of the mechanisms of
drug resistance.
Results
Effects of TKIs on the Induction of Apoptosis in BCR-ABL
+ and 2 Cells
For the in vitro screening of TKI-dependent proteome changes,
we used a well-established murine CML model: Ba/F3 cells, an
immortalized murine bone marrow-derived pro-B-cell line, are
retroviraly transfected with either wild type (p210) or mutated
BCR-ABL isoforms (M351T, T315I). In order to compare the
efficacy of the different TKIs, concentrations with similar
Figure 1. Schematic representation of meso network architecture and experimental design. (A) Exemplifies an abstract meso-scale
network representing (abstract) pathways of drug action of drugs A and B on induction of proteins (red, yellow and orange bullets). Drug A uses two
pathways (blue and black), whereas the blue pathway induces expression shifts only on a subset of the proteins (red, yellow), whereas the black
pathway induces expression shifts in all proteins. Drug B acts only via one pathway which joins the black pathway of Drug A in an abstract node
(represented by the green bullet). The mutation inhibits both pathways between the green and blue bullet resulting in an interference with drug
induced expression shift for all proteins. The blue pathway from Drug A to the proteins, however, is not affected by the mutation. Hence the
mutation may have a strong impact on the efficacy of drug B, whereas the profile of action of drug A is only altered by the mutation. (B) Imatinib
sensitive and resistant cells were treated with four tyrosine kinase inhibitor and mesoscale network were reengineered based on specific proteome
expression patterns.
doi:10.1371/journal.pone.0053668.g001
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inhibitory activity (close to the respective IC50s of the TKIs) were
used (Figure 1B). Induction of apoptosis served as an indicator for
efficient inhibition of BCR-ABL activity and was measured by
caspase-3 activity in flow cytometry. Figures 2A–C show a
comparable degree of induction of apoptosis in TKI sensitive
cells indicating a successful inhibition of BCR-ABL. Consequently,
a distinct response pattern was observed by treatment with TKI of
the first (IM), second (NILO, DASA) and third generation
(DANU) in BCR-ABL positive Ba/F3-p210 cells (Figure 2A)
while no apoptosis was observed in BCR-ABL negative Ba/F3
control cells (not shown). Expectedly, in cells harboring the low-
level IM resistance conferring M351T mutation, DASA and
NILO were found to be active (Figure 2B). However, in cells
transfected with the highly resistant T315I mutant, only the third
generation inhibitor DANU, a dual inhibitor of BCR-ABL and
aurora kinases A, B and C, was capable of induction of apoptosis.
As expected the efficacy of DANU was slightly more pronounced
in the T315I mutant as compared to the wild type form of BCR-
ABL (Figure 2C). This effect is based on particular structural
properties of DANU which allows binding to the active center of
the mutant kinase [42].
Identification of Differentially Regulated Proteins in BCR-
ABL+ cells Treated with TKIs
Sets of independent triplicates for each BCR-ABL isoform
treated for 24 hours with the different TKIs were analyzed and
compared to the solvent control (DMSO) by two-dimensional gel
electrophoresis (2D-PAGE) analysis. As expected and in line with
the reported alterations of caspase-3 activity, a wide response to
the TKIs was observed in wt Ba/F3-p210 cells. In total, 68 spots
with a differential expression of at least 2-fold and statistical
significance were identified (Table S1). For each BCR-ABL
isoform a specific drug profile as well as a proteome map with the
individually regulated spots was generated. Thus, in Ba/F3 cells
harboring the wt BCR-ABL, 46 (35 up and 11 down), 24 (20 up
and 4 down), 34 (28 up and 6 down) and 10 (6 up and 4 down)
specific spots were detected secondary to treatment with IM,
NILO, DASA or DANU, respectively.
In Ba/F3 cells harboring the low grade IM resistant mutation
M351T, IM changed the expression of one spot (0 up and 1 down)
while NILO altered the expression of 5 spots (3 up and 2 down),
DASA of 28 spots (28 up and 0 down) and DANU of 8 spots (3 up
and 5 down) (Table S2). As expected, alterations reported in Ba/
F3 cells transfected with the highly resistant T315I mutation were
minor. Thus, only eight altered spots (2 up and 6 down) were
reported in IM, five (2 up and 3 down) in NILO and two (0 up and
2 down) in DASA treated cells. However, in DANU treated cells
Figure 2. A–F: Apotosis induction after treatment with different TKI and hierarchical clustering of differential expressed protein. (A)
Ba/F3-wt. –p210, -M351T und –T315I cells were incubated with Imatinib (IM), Nilotinib (NILO), Dasatinib (DASA) or Danusertib (DANU) for 24 hours.
After 2D-PAGE changes in the protein expression profile was analyzed using Delta-2D software to identify drug-specific. (B–E) Caspase 3 activity in
BCR-ABL negative Ba/F3 cells (B), wildtype IM sensitive BCR-ABL positive Ba/F3-p210 cells (C) and mutated IM resistant BCR-ABL positive Ba/F3-
M351T-(D) and BAF3/2T315I cells. Asterisks indicate significant changes compared to DMSO. Unsupervised clustering (euclidean distance measure
and the ’average’ agglomeration method) was performed using the log transformed expression protein values for (D) Ba/F3-p210, (E) Ba/F3-M351T
and (F) Ba/F3-T351I cells. The samples are shown horizontally, the proteins vertically. The dendrograms represent the distances between the clusters.
In the upper color bar, the upregulated proteins are marked in red, the down regulated are shown in green.
doi:10.1371/journal.pone.0053668.g002
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14 spots (12 up and 2 down) were found to have changed
expression (Table S3). Secondary to the identification of the
quantitatively altered protein spots by Delta-2D software a
characterization by mass spectrometry was performed.
TKI Specific Effects on Protein Expression in IM Sensitive
and IM Resistant Ba/F3 Cell Lines
To analyze a potential correlation between the level of
resistance to the respective TKIs and a similar protein expression
pattern, cluster analyses were performed (Figure 2D–F). Remark-
ably, hierarchical cluster analysis based on these candidate
proteins identified similar protein expression patterns for IM,
NILO and DASA when compared to DANU in Ba/F3-p210 cells
(Figure 2D). However, in TKI resistant cell lines, clustering was
less pronounced (Figure 2E–F). The evaluation of changes of the
protein expression patterns depending on the applied drug and the
BCR-ABL mutation status allows us to describe more closely on
target and off target nature of effects of the respective TKIs.
Furthermore, the comparison of the protein expression patterns of
the different TKIs with known off-target activity (such as the SRC
family of kinases in the case of DASA of the Aurora kinases in the
case of DANU) in wt BCR-ABL positive Ba/F3-p210 cells allows
to characterize protein expression changes observed as a result of
inhibition of BCR-ABL as opposed to changes attributable to
inhibition of off target kinases.
Surprisingly, by analyzing overlapping expression patterns of
candidate proteins induced by the different TKIs in the individual
wild-type and mutant cell lines, we found that in Ba/F3-p210 cells,
only two of 45 proteins revealed consistently altered expression
characteristics secondary to treatment with all four TKIs
(Figure 3A). The highest level of consistency was detected for
IM, NILO and DASA implying a similar efficacy profile.
However, effects that could be assigned to individual cells
specifically were very limited, e.g. secondary to IM only five
proteins were identified, one after treatment with DASA or
DANU and no specific proteins were found in cells treated with
NILO (Figure 3A). No proteins simultaneously regulated by all 4
TKIs were observed in the low-level IM resistant Ba/F3-M351T
mutant (Figure 3B) nor in highly resistant Ba/F3-T315I cells
(Figure 3C). Strongest drug specific effects were detected in DASA
treated Ba/F3-M351T cells with 13 proteins differentially
regulated whereas DANU revealed four and both IM and NILO
only revealed one compound-specific protein each (Figure 3B).
Expectedly, in Ba/F3-T315I cells, DANU revealed the strongest
drug specific effect with four compound-specific proteins showing
altered expression. Surprisingly, a similar degree of compound-
specific effect was observed for IM. However, due to the fact, that
T315I is highly IM resistant, these effects were attributed to off
target effects. NILO induced one specific change while DASA did
not show any specific alterations at all (Figure 3C). In order to
verify changes in the expression or modification pattern of two of
the identified proteins, we performed Western blot analysis for the
eukaryotic initiation factor 5A (eIF5A) and for tissue transgluta-
minase 2 (TGM2). For eIF5A a two-dimensional Western blot
revealed the appearance of one additional spot at a pI of 6.1 after
treatment with 1 mM IM for 24 hours. This finding is consistent
with the Commassie stained large 2D-gels and can be interpreted
as a posttranslational modification of eIF5A, which leads to a shift
of the protein to a more basic pI (Figure 4A–B). For TGM2 the
Western blot analysis confirmed an IM dependent up regulation of
the protein. In the Commassie stained 2D-PAGE (Figure 4C) and
in the one-dimensional Western blot (Figure 4D) TGM2 showed a
clear upregulation.
Meso Scale Network Models for Action of TKIs
Meso scale networks in BCR-ABL wild-type Ba/F3-p210
cells. In wild type Ba/F3-p210 cells, 37 proteins with significant
differential expressions were identified. As depicted in Figure 5A,
for IM, DASA and NILO, the induced expression changes for all
37 proteins show a high mutual correlation, such that the induced
expression for all proteins can be approximated by a joint factor
FA (red stars) identified using standard factor analysis. However
for DANU, a systematic and significant deviation from the joint
expression factor was observed (Figure 5B). This correlated
behavior of the 37 proteins is visualized by Figure 5C depicting
the protein expressions under all four drugs. IM, DASA and
NILO show structurally similar behavior with almost uniform
correlation to the factor FA, whereas the response on DANU can
be separated into at least two protein groups. The first protein
group (group 1, i.e. lower population of red stars, Figure 5C) is
correlated to FA, but shows significantly less sensitivity when
compared to IM, DASA or NILO, whereas the second protein
group (group 2, upper population of red stars, Figure 5C) shows
high correlation to FA with high sensitivity. The separation into
multiple protein groups with heterogeneous activation by the drug
is supported by the analysis of the distribution of the residues of the
protein expressions from the factor model. A Lilliefors-test for
normal distribution of the deviation has been performed for all
four drugs. The respective p-values, depicted in Figure 5D,
indicate that the deviations for IM and NILO are normal
distributions which are due to noise, whereas the very low p-value
for DANU indicates that the respective protein expressions cannot
be explained by one factor FA plus random noise alone. For
DASA, the respective p-value is slightly higher than 5%, such that
a separation into multiple protein groups cannot be excluded. The
protein groups for DANU and DASA have been separated using
regression clustering (Table S4 for DANU, see supplement). These
findings can be interpreted as depicted in Figure 5E. In Ba/F3-
p210 wild type cells, IM, DASA and NILO activate pathways
which join together in a functional node (blue bullet) which
activates all 37 proteins in a coherent manner according to the
stimulation of the joint node. In contrast, DANU stimulates the
joint node with significantly less impact, (protein group 1), whereas
the proteins in group 2 show a similar (or slightly higher) response
to stimulation compared to stimulation with IM, DASA or NILO.
The black block in Figure 5E (as well as in Figure 6D) indicates the
model for induction of the protein expression by the main
pathway, in this paper represented by a linear model. The red
block in Figure 5E (as well as in Figure 6D) indicates the common
inhibition of the drug action for protein group via the main
pathway. Hence we propose (at least one) additional component
for the mechanism of induction of protein expression by DANU
which is depicted in Figure 5E. The findings can be explained if
one assumes that DANU activates the joint mechanism similar to
the other three drugs, but it induces a second MoA as well. This
second MoA reduces the induced expression of the group 1
proteins.
Meso scale networks in BCR-ABL mutated BaF/3-M351T
cells. The induced protein expressions of 17 proteins both in
Ba/F3-M351T cells as well as in Ba/F3-p210 cells are depicted in
Figure 6A. Due to the logarithmic scale, induction is represented
by positive values and suppressions by negatives. The overall
induced protein expressions in BAF/F3-M351T and Ba/F3-p210
cells show a linear correlation on the logarithmic scale, which
differs, however, between the various TKI’s. Figure 6B shows the
slopes of induced protein expression for the individual TKI’s for
Ba/F3-MT351T – cells compared to Ba/F3-p210 wild type cells
as calculated from Figure 6A using linear regression. Low values
Meso Scale Networks and Drug Mode-of-Action
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Figure 3. A–C: Venn diagrams for representation of drug specific protein expression. Venn diagrams illustrated the drug specific effects in
different cell lines: (A) Ba/F3-p210, (B) Ba/F3-M351T and (C) Ba/F3-T351I cells. The numbers inside the circles represent the number of regulated
proteins.
doi:10.1371/journal.pone.0053668.g003
Figure 4. A–D: Western blot analyses revealed posttranslational modification of eIF5A and up regulation of TGM2 after treatment
with IM. (A) Enlarged regions from a coomassie stained 2D-PAGE from Ba/F3-p210 cells after treatment with IM or DMSO as a control. The arrows
indicate two spots for eIF5A, one at pI of 5.2 and the other one at a pI of 6.1. The latter appeared after IM treatment. (B) 2D-WB validated the
appearance of a second spot for eIF5A at a pI of 6.2 after IM treatment. (C) Enlarged regions from a coomassie stained 2D-PAGE from Ba/F3-p210 cells
after treatment with IM or DMSO as a control. One spot for TGM2 (arrow) demonstrated an increased expression after IM treatment. (D) The increased
expression of TGM2 after treatment with rising concentrations of IM could be validated in human Bcr-Abl K562 cells.
doi:10.1371/journal.pone.0053668.g004
Meso Scale Networks and Drug Mode-of-Action
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indicate a strong suppression of drug induced protein expression
by the mutation, whereas a value around one indicates that the
mutation has no significant effect on the MoA’s of the respective
drug. Apparently the induction of protein expression by IM is
significantly suppressed by the M351T-mutation, whereas the
MoA’s of DANU are apparently not effectively inhibited by the
M351T-mutation. The MoA’s of DASA and NILO appear to be
slightly affected by the mutation. Surprisingly all 17 proteins show
a significant, coherent increase of expression in Ba/F3-M351T
cells compared to Ba/F3-p210 wild type under NILO treatment
(Figure 6C). These findings suggest that the protein expression is
controlled by a more detailed mechanism than described above.
The joint node controlling the coherent protein expression, as
observed in Ba/F3-p210 wild type cells, has to be split into at least
two components, one (red bullet) is affected by the M351T-
mutation, the other (blue bullet) is not (Figure 6D). IM interacts
only with a pathway passing the red node, whereas DASA and
NILO affect both nodes. DANU apparently affects only the blue
node. Moreover NILO induces the overall expression level
(indicated by green bar).
Meso scale networks in BCR-ABL mutated BAF/F3-T315I
cells. In Ba/F3-T315I-mutated cells compared to Ba/F3-p210
wild type cells, 11 proteins with significant differential expression
could be identified (data not shown). The mean expressions under
IM and DASA are significantly reduced compared to Ba/F3-p210,
whereas the mean logarithmic expressions of NILO and DANU in
Ba/F3-T315I cells do not significantly differ from the mean
expressions in Ba/F3-p210 wild type. Apparently, in contrast to
M351T-mutated cells, no correlation of the expression under
T315I-mutation and wild type p210 can be found, hence linear
regression analysis is not applicable for analysis of the T315I-
mutation. This finding indicates that the T315I mutation appears
to interrupt the edge between both control nodes to the protein
expression.
Meso Scale Network Models for Apoptosis Induction
For a subset of 10 proteins induced in all cell lines, factor
analysis of the induced expression shifts for all four drugs in all cell
lines shows a significant co-regulation of the proteins. Using factor
analysis the joint induced expression of the proteins was quantified
by the factor FA. The Pearson correlations between the induced
protein expressions and the joint induction FA show heteroge-
neous regulation features (Figure 7A). Five proteins (P63260,
P14733, Q61937, P62962, P60710) show linear correlation r..9,
one protein (Q64674) has r = .78. However, the other 4 proteins
show significantly lower co-regulation between their expression
and FA, indicating that the respective protein expressions are
induced by at least two disjoined functional pathways.
Figure 5. A–E: Meso scale networks Ba/F3-p210 cells. (A) High degree of co-regulation across the protein set for IM, DASA and NILO, which can
effectively represented by the mean component of factor analysis. (B) Significant deviations for a small set of proteins for DANU suggesting the use
of the more stable factor analysis instead of PCA for reduction of dimension. (C) Analysis quantitatively the amount of induction of protein
expression, which is associated with the activation of the dominant mechanisms, quantified by the mean component of factor analysis. Whereas a
good and almost similar behaviour for IM, DASA and NILO is observed, DANU activates the proteins in two clearly separated modes (indicated by the
upper and lower line of red stars). This finding is supported by quantitatively testing the distribution of the residuals of protein expressions with
respect to the linear regression model given by the mean component of factor analysis. (D) Apparently only DANU induces residuals with significant
non-gaussian noise indicating the existence of two separate mechanisms of protein induction. (E) Structure of meso scale pathways for induced
protein expression. Black block represents induction of the protein expression by the main pathway, whereas the red block is indicating an inhibition
via the main pathway.
doi:10.1371/journal.pone.0053668.g005
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In order to identify a differential activation profile of the
functional pathways by one of the four TKIs, we performed the
same analysis omitting the data from each drug individually. Most
significant improvement in co-regulation between FA and the
induced protein expressions was found when DANU was omitted
(Figure 7B) indicating that DANU induces secondary functional
pathways significantly stronger than the other TKIs.
Apparently the expressions of 7 proteins are not affected by
specific mechanisms of the MoA of DANU, whereas 3 proteins
(Q8R4N0, P00493, Q9R0Q7) show a significant increase of co-
regulation with the joint protein expression quantified by FA when
DANU is omitted. This result indicates again the existence of a
functional pathway to protein expression which is only induced by
DANU, but not affected by the other TKIs.
In order to identify co-regulation between induction of
apoptosis and overall protein expression, we analyzed the
correlation between induced apoptosis rate and the mean
component of protein expression discussed above. The results,
depicted in Figure 7C, show a surprisingly good correlation
between the sum of the induced protein expressions and induced
apoptosis. This correlation holds for almost all TKIs and all cell
lines, only two outliers (IM in Ba/F3-p210 cells and DASA in Ba/
F3-M351T cells) have been found. Detailed analysis of the results
depicted in Figure 7C shows that omitting DASA from the analysis
results in a reduction of the mean deviation from the linear
relationship between the protein induction and apoptosis induc-
tion by 18%. We find that the mean protein induction of DASA in
the three cell lines is significantly higher than expected by the
induction of apoptosis. These results suggest that, in contrast to the
other TKI’s, DASA can significantly induce protein expression
aside from induction of apoptosis. However, as indicated in
Figure 7C, the impact of the drugs on protein expression in
relation to induction of apoptosis depends strongly on the type of
mutations in the cell lines. Surprisingly we find no significant
deviation from the mean protein expression – apoptosis model for
DANU, despite, as discussed above, DANU apparently activates a
functional pathway which is not induced by the other TKIs.
In summary, the integrated structural analysis of apoptosis
induction and protein expression leads to the following findings: i)
A group of five proteins (P63260, P14733, Q61937, P62962,
P60710) is induced in a highly coherent manner by all TKI and in
all cell lines and dominate the main expression component. Hence
these proteins may be controlled by secondary response mecha-
nisms which are not specific to the functional pathways of direct
drug action. ii) DANU induces a secondary functional pathway
which has similar impact on induction of apoptosis than the
primary pathway. iii) DASA induces significantly more protein
expression in relation to induction of apoptosis than the other
Figure 6. A–D: Meso scale networks Ba/F3-M351T. (A) Shows the protein expressions for wt and T351 cell type for all drugs. (B) Shows the
sensitivity of protein expression with respect to the dominant activation mechanism, quantified by the mean component of factor analysis. (C)
Shows, that surprisingly the overall level of protein expression induced by NILO increases, although the sensitivity decreases. (D) Shows the
modifications which are induced by the analysis of the M351I mutation to the meso scale pathway network depicted in Figure 5E. Black block
represents induction of the protein expression by the main pathway, whereas the red block is indicating an inhibition via the main pathway. Green
block represents the unique effect of NILO on the overall protein expression level.
doi:10.1371/journal.pone.0053668.g006
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drugs. Hence, DASA may show more unspecific effects at the
same level of apoptosis induction than the other TKIs. These
findings are consistent with a meso scale model for TKI action,
which is depicted in Figure 7D, without claiming quantitative
interpretation.
Discussion
Given the lack of selectivity of most TKIs, unexpected side
effects of this novel class of drugs are common however differing
between compounds. Hence, an easy, high-throughput and
unbiased assessment of drug action using a broad panel of drug-
induced protein expression data would be of high interest for
optimization of drug development. We have developed a modeling
approach for reengineering of meso scale networks for assessment
of drug action based on a broad panel of proteomics data which
are not necessarily involved in the direct mode of action. Although
the meso scale networks do not reflect the detailed information
with respect to the proteins involved in the MoA, they provide a
useful and visual representation of the full systems of pathways
involved in the modes of action with a focus on their cross-talk
[27,43,44]. Our approach does not require a priori information
with respect to the modes of action. Nevertheless, it provides
critical information for assessment of the drug action in clinical
use. Because it is sufficient to unravel the necessary information
from secondary effects, the approach allows an unbiased
assessment of drug activity. Employing clinically used BCR-ABL
inhibitors in different experimental settings, including resistant and
non-resistant cell lines, we have demonstrated here how the
interaction of multiple MoA can be identified and evaluated using
pathway networks on a mesoscopic scale. Furthermore, we show
how protein expression data and data about apoptosis induction
can be integrated for evaluation of target and non-target drug
effects. In contrast to many other studies [45,46] which are based
on gene expression data, our conceptional approach is based on
expression data obtained from a global proteomics approach. In
comparison to gene expression analysis, the evaluation of the
global proteome expression allows for a direct observation of
changes in protein expression and even more so in post
translational modification of proteins [47]. Using this broad
proteomics approach facilitates the identification of unexpected
Figure 7. A–D: Meso scale network models for apoptosis induction. (A) Distribution of the Pearson coefficient between individual protein
expression and the mean component of factor analysis which represents the dominant co-regulation mechanism. (B) Shows that the proteins can be
decomposed into two groups differing with respect to the impact of DANU. Most proteins show no different co-regulation behaviour if DANU is
omitted from the data set, whereas three proteins show a significantly higher degree of co-regulation (increased r value) when DANU is omitted
indicating a second mode of action of DANU. (C) Shows that with exception of two treatments the mean protein expression, represented by the
value of the mean component of the factor analysis (y-axis) is correlated to the observed induction of apoptosis (x-axis) indicating a similar efficacy in
apoptosis induction for most drugs. The exceptions indicate that protein expression is induced which does not contribute to apoptosis induction. (D)
Depicts the meso scale set of pathways, which fits two the observations.
doi:10.1371/journal.pone.0053668.g007
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drug effects (which may remain hidden in analysis restricted to
pre-selected set of proteins) in an unsupervised approach.
The proteome data described here clearly show, that the
different 1st, 2nd and 3rd generation TKIs investigated here induce
a distinct pattern of protein expression changes which correlates
with the drug sensitivity of the individual cell lines studied. These
observations are in agreement with the known differences in the
inhibitory profile of these TKIs [48,49,50,51]. However, as these
studies performed by techinically different chemical or affinitiy
purification proteomics approaches which were conducted to
identify direct TKI- or BCR-ABL-binding targets rather than
effects of TKI inhibition on the protein expression profile of BCR-
ABL positive cells, we could not detect any overlap between the
proteins identified in these studies and in our proteome screen.
For some of the identified proteins, a connection to BCR-ABL
signaling has already been described in previous studies [52]. In
particular, the effects of BCR-ABL on actin (which is differentially
regulated in our proteome screen) have been linked to the
enhanced migration of BCR-ABL positive hematopoietic cells
from the bone marrow to the peripheral blood [53]. Heat shock
protein 70 (Hsp70) and 90 (Hsp90) are other proteins reported in
our proteome analysis that are known targets of BCR-ABL
[54,55]. Interestingly, we identified eIF5A as regulated after
treatment with IM, NILO and DASA in Ba/F3-M351T cells. This
is in agreement with our recent studies in human K562 cells [52].
Although we identified known targets of BCR-ABL, for most of
the described proteins in our proteome screen there are so far no
published evidences for a BCR-ABL dependent regulation.
Therefore, these data can be used as a basis for further
investigation in BCR-ABL signaling. In particular, further
investigations in BCR-ABL dependent regulation of TGM2,
which is supposed to be involved in apoptosis and adhesion,
seems to be worthwhile and are ongoing [56].
In an attempt to demonstrate whether a simplified and coarse-
grained approach would gain insights into the differences in of
MoA patterns between the compounds studied, we employed
meso scale network approach in order to model our protein
expression data.
We further analysed the resulting meso scale networks in order
to identify similarities and differences between TKIs used for the
same clinical indication, i.e. the treatment of Chronic myeloid
leukemia. Existing experimental and clinical data indicate that IM,
NILO and DASA activate a common MoA, i.e. inhibition of
BCR-ABL. In contrast and in addition to inhibition of BCR-ABL,
DANU has been shown to inhibit the Aurora family of kinases
[38,42]. Interestingly this phenomenon is indeed reflected by a
significantly distinct protein induction profile of DANU as
opposed to the other TKIs studied. Even more so, although IM,
NILO and DASA clearly exhibit a common dominant MoA in
wild-type Ba/F3 cells, they differ significantly with respect to their
inhibitory profile when BCR-ABL is mutated in Ba/F3-M351T
and Ba/F3-T315I cell lines. Therefore, the profiles of induction of
protein expression of IM, NILO and DASA show significant
differences, especially if the primary MoA is inhibited by
mutations, such that induction of apoptosis is reduced. Whereas
NILO appears to be rather specific, DASA induces significant
protein expression changes which do not seem to contribute to
apoptosis induction in Ba/F3-M351T cell lines. It can only be
speculated that based on the specific kinase inhibitory spectrum of
DASA, inhibition of members of the SRC-family might contribute
to this phenomenom. Future comparisons using alternative
combined BCR-ABL/SRC family kinase inhibitors such as
Bosutinib might provide additional insight regarding the relevance
of SRC inhibition both for induction of apoptosis in leukemic cells
as well as for the side effect profile of such TKIs [35,36,57]. In
contrast to IM, NILO and DASA, DANU shows a very different
activation profile. Apparently DANU activates a second pathway
which is not affected by the M351T and T315I mutations. This
second MoA most likely representing the inhibition of the Aurora
family of kinases pathway is almost as efficient in induction of
apoptosis as the common primary MoA.
The drawback of the approach in general is the restriction to
experimental settings where a clear feed-forward structure of the
information flow can be guaranteed. Accordingly, the method can
be applied if the MoA of the drug action affects the readout data,
here protein expression, but the induced protein expression does
not affect the structure of the MoA. If the latter case happens, then
validity of the underlying mathematical approach cannot be
guaranteed to date. As a consequence, the extension of the method
to other drugs than TKI’s can be expected if the drugs act
primarily via a well defined set of MoA’s which are not structurally
disturbed by the cellular response on the drug itself. Hence,
extension to classes of drugs acting by very broad range of targets
or inducing a very strong stress response has to be evaluated in
future. As unraveling of recursive networks remains an instrinsic
challenge for any method explored so far, we see no signficant
restriction of the value of the described method as a complemen-
tary approach.
Preliminary results indicate that the method can be extended to
data sets representing short term drug action, such as phospho-
proteomic data [manuscript in preparation]. Future research has
to evaluate it`s applicability to data sets reflecting long-term
response, such as transcriptomics or epigenetics data. However,
more advanced mathematical methods may be able to overcome
the abovementioned limitations of the meso-scale approach.
Earlier results [Schuppert A, et al.: Method for identifying
predictive biomarkers from patient data. Patent WO/2007/07/
9875 (2006)] indicate options for extension towards heterogeneous
data sets.
In conclusion, our approach led to the identification of direct
and indirect drug effects in a well-defined model system and
should be amendable to various new drugs. Therefore, combina-
tion of broad proteome profiling and meso scale network
reengineering provides a versatile tool to map a drug’s direct
and indirect target pathways in a single set of experiments.
Because of it`s adaptability to other model senarios, this approach
should prove valuable at various stages of drug discovery as well as
in translational studies of drug action in patient tissues. It
represents a powerful method allowing the identification and
assessment of multiple MoA using only unbiased protein
expression data. Therefore it could contribute significantly to the




IM (kindly provided by E. Buchdunger, Novartis, Basel,
Switzerland), DANU (kindly provided by Nerviano Medical
Sciences, Milan, Italy), NILO (kindly provided by Novartis
Pharma, Basel, Switzerland) and DASA (kindly provided by
Bristol-Meyers Squibb, New York, NY) were applied according to
the different experimental protocols. All tyrosine kinase inhibitors
were stored at –20uC as stock solutions (NILO 883mM, DASA
19.76 mM, DANU 10 mM) in DMSO or 50% DMSO (Imatinib
1.7 mM, [DMSO]/H2O [1:1]). Fresh dilutions in complete media
were prepared prior to the experiments. The highest concentration
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of DMSO in cell culture medium was less than or equal to 0.1%
and did not have any effect on cell growth.
Cell Culture Techniques
Ba/F3 and K562 cells were obtained from DSMZ (Bielefeld,
Germany). Ba/F3-p210, -T315I and -M351T, and cells were
kindly provided by C.L. Sawyers (University of California at Los
Angeles) [58,59]. All cell lines were cultured in RPMI 1640
medium (Gibco-BRL, Invitrogen, Paisley, United Kingdom)
containing 10% fetal calf serum (FCS) (Biochrom KG, Berlin,
Germany) and for Ba/F3 cells 1 ng/mL recombinant murine
interleukin-3 (IL-3) was added. Cells were incubated at 37uC in a
humidified atmosphere with 5% CO2.
TKI Treatment for Proteome Analysis
Ba/F3-p210, -T315I and -M351T cells were treated with TKIs
(IM 1 mM, NILO 50 nM, DASA 5 nM, DANU 0.4 mM),
harvested and washed three times with PBS after 24 h.
Protein Preparation, Two-dimensional Gel
Electrophoresis (2D-PAGE) and Image Analysis
Protein preparation and 2D-PAGE were performed as de-
scribed previously [52,60]. In brief, cells were lysed in sample
buffer (9 M urea, 4% CHAPS, 0.5% Pharmalyte 3–10 IEF
(Amersham Biosciences), 10 mg/mL bromophenol blue) followed
by centrifugation at 12 000 g for 5 minutes. Samples were applied
to linear gradient Immobiline Dry Strip (IPG Strip pH 4–7,
24 cm, Amersham Biosciences, Uppsala, Sweden) by in-gel
rehydration. After isoelectric focusing using the Protean IEF cell
(Bio-Rad, Hercules, CA) at 10 000 V for approximately 80 kVh,
IPG strips were equilibrated for 2615 minutes in 6 M urea, 4%
SDS, 50 mM Tris-HCl, pH 8.8, containing 1% DTT for the first
or 4.8% iodoacetamide for the second period of equilibration.
Strips were placed on vertical SDS-PAGE gels and overlaid with
0.6% agarose. SDS-PAGE was carried out with the Protean Plus
Dodeca Cell (Bio-Rad, Hercules, CA) using 15% SDS-polyacryl-
amide gels (27 cm621 cm61.5 mm). Two-dimensional gels were
stained overnight with colloidal Coomassie (0.2% Coomassie
Brilliant Blue R250), followed by destaining for 1 day. All
experiments were performed in triplicates, revealing comparable
results. The 2D-gels were scanned with a GS-800 Calibrated
Densitometer (Bio-Rad, Hercules, CA). Images were warped
group-wise using Delta2D 3.6 software (Decodon GmbH,
Greifswald, Germany). Spot patterns were detected on fused
images (gained from all gels) using the average intensity algorithm
and retransferred to the original images for 100% matching
efficiency. Spot quantification was based on normalized relative
spot volume (% volume) as exported from the statistics table of the
Delta2D software.
Protein Identification by Mass Spectrometry
Protein identification was performed as described recently
[60,61]. In brief, trypsin digestion and spotting onto the
MALDI-targets were performed in the Ettan Spot Handling
Workstation (Amersham-Biosciences, Uppsala, Sweden). The
MALDI-TOF measurement of spotted peptide solutions was
carried out on a 4800 MALDI TOF/TOFTM Analyzer (Applied
Biosystems, Foster City, USA). For protein identification peptide
lists were compared with the SwissProt rel.56.1 restricted to
murine taxonomy using the Mascot search engine 2.2 (Matrix
Science Ltd, London, UK). Peptide mixtures that yielded a
mowse score of not less than 55 for SwissProt results were
regarded as positive identifications. Additionally to improve
probability at least one peptide was sequenced with a significant
ion score of above 27.
Cluster Analysis and Generation of Venn Diagrams
Cluster analysis and the generation of venn diagrams were
performed with the statistical language R (http://www.R-project.
org). The heat maps from the hierarchical cluster analysis were
generated using as a metric Pearson’s correlation and the ’average’
agglomeration method. For the venn diagrams only proteins were
selected showing a p-value.=95% (from the Lilliefors-test) and a
relative expression value over 1.
Western Blot Analysis
For protein extraction, K562 cells were homogenized on ice in
lysis buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
1% NP-40, 0.25% Na-desoxycholate, 5 mM EDTA, 1 mM NaF,
25 mM Na3VO4, and 0.1 mM PMSF. Lysates were left on ice for
10 minutes, and cellular debris was pelleted at 20 000 g for 20
minutes at 4uC. The supernatant was frozen at –80uC. The
protein concentration of the lysate was determined with the BCA
Protein Assay Kit (Pierce, Rockford, IL). Proteins (20 mg) were
separated by 12% SDS-PAGE and transferred onto PVDF
membranes with the Bio-Rad Transblot system. After blocking
in PBS-Tween/3% wt/vol BSA for 30 minutes, membranes were
incubated in primary antibody diluted in PBS-Tween/3% wt/vol
BSA. The following primary antisera were used: rabbit anti-
Transglutaminase 2 (Abcam, ab421) (1/1000,), mouse monoclonal
anti-TGM2 (1/250 ) (Santa Cruz, sc-48387), anti- GAPDH (1/10
000). After washing, membranes were incubated for 1 hour with
HRP-conjugated rabbit anti–goat immunoglobulin (1/10 000) or
with rabbit anti–mouse immunoglobulin (1/10 000) (both from
Amersham Pharmacia Biotech UK, Little Chalfont, Buckingham-
shire, United Kingdom), diluted in PBS-Tween/3% wt/vol BSA.
After washing, the Pierce ECL Western Blotting Substrate
(Thermo Fisher Scientific, Rockford) was used to visualize the
secondary antibody.
Mini-2D Western Blotting Analysis (2D-WB)
2D-WB analysis was performed as previously described [62,63].
In brief, protein samples were prepared as described for 2D-
PAGE. 125 ml solution containing 30 mg of protein were loaded on
a linear gradient Immobiline Dry Strip (IPG Strip pH 4–7, 7 cm
Amersham Biosciences), followed by rehydration of strips and
isoelectric focusing (IEF) using the Protean IEF cell. After
equilibration strips were directly loaded onto 15% SDS-polyacryl-
amide gels, overlayed with 0.6% [w/v] agarose in dH2O, and run
3 h at 65 V. Consecutive transfer, blocking, incubation with
antibodies and detection steps were carried out as described for the
Western blotting experiments, see above.
Reengineering Meso Scale Models for the MoA of TKIs
In order to unravel insight into the mechanisms of protein
expression and induction of apoptosis by TKIs in cells with
heterogeneous mutation profiles, we aimed first to establish a meso
scale network model for the interaction between the TKIs and
mutations. In the second step we developed a model to assess the
efficacy of the TKIs, quantified by the induction of apoptosis, in
relation to their overall protein induction profile. As outlined
above, meso-scale network reconstruction aims to identify the
network topology of the relevant pathways as well as their
interaction without explicit use of a priori information. In contrast
to network reengineering approaches fitting more or less detailed
mechanistic models to the data, we intend to provide a proteome-
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wide, unbiased assessment on the rough structure of the drug
induced mechanisms as well as their interaction. Here we are
interested in the proteome-scale structure of interactions of the
MoA’s of the drugs with the mutations as well as the existence of
multiple, drug induced effects. We do not intend to identify the
detailed biological mechanisms behind the identified MoA’s and
their interaction, which must be done in a complementary follow-
up analysis. The mathematical concept has been described
recently [41] and is based on the identification of intrinsic
correlation structures in the multivariate data sets which are
assessed from combinatorial experiments, in contrast to model
fitting. In order to exploit the multiple readouts (induced protein
expressions and apoptosis), we extended the methods described in
[41] by the analysis of the behavior of correlations in wild type and
mutated cells. As depicted in Figure S1A–B, the localization of the
mutation-induced breakpoint of drug action pathways may be
reconstructed by analysis of the correlations of multiple drug-
induced readouts between wildtype and mutated cells. Identifica-
tion of correlation structures means the identification of sets of
input variables (TKI’s and mutations) and output variables
(protein expression and apoptosis induction) which show a
significant degree of correlation in specific sets of the combina-
torial inputs. The required decomposition of data with respect to
mutual correlations in input and output variables can be
performed by clustering. However, due to the small set of
combinatorial data, clustering may result in a high degree of
instability. However, preliminary analysis showed that the
correlations sets showed a hierarchical order of size and
correlation. Hence we used the more robust factor analysis (as
implemented in Matlab) in an iterative approach, in each step
identifying the ‘‘leading’’correlation sets and analyzing the
apparent ‘‘outliers’’ in the following step.
The method as described in [41] [27] allows the identification of
non-linear mechanisms, however the identification of the related
non-linear correlations using Spearman or Kendall tau instead of
Pearson coefficient require large data sets which are not available
here. As all correlations appeared to be almost linear, the
substitution of non-linear correlation methods by linear correlation
analysis was applied significantly improving the stability of the
procedure. Combining the multiple linear correlations allowed the
identification of the required information with respect to the
network topology even from relatively small data sets. So this
analysis shows the feasibility proteome wide network reengineering
allowing an unbiased assessment of drug induced mechanisms
which would not be accessible using detailed network reengineer-
ing.
The modeling approach used the combinatorial information
with respect to mutation profile and stimulation by TKIs as input
variables and the protein expression data as well as the induction
of apoptosis as multiple and heterogeneous readouts of the cellular
system.
In a first step we identified a model for the pathways and their
interaction with mutations describing the induction of protein
expression by the TKIs. The analysis was performed using the
expression data of all proteins with significant effect of the drugs
(inhibition or induction of expression), proteins without significant
effect were neglected. If multiple spots were available for one
protein, the mean of all spots encoding the protein was used as the
effective protein expression. The analysis was performed using
Matlab, Statistics toolbox (version R2010b, The Mathworks Inc.).
The protein expressions xi(uj, m1) for all available proteins i,
induced by one of the four kinase inhibitors uj = [0,1], j = 1…4,
and the mutations ml l = 1…3 (wt, T351 and T310), were
correlated with each other. As described in [41], the meso scale
network structure for the mechanism acting between kinase
inhibition and protein expression can be established by joint
analysis of all pairwise correlations of the protein expressions. If no
correlations can be found, the function describing the protein
expression in terms of kinase inhibition has to be described using a
black-box model as indicated in Figure S2A. However, often factor
analysis shows correlations between the protein expressions. Then
all protein expressions under all kinase inhibitions can be
expressed by a linear factor-model using m (m small) factors ck





where xi(u1,…,u4, m1,..m3) describes the expression of protein i
depending on the combination of administration of the four kinase
inhibitors and mutations. The term ei represents the deviation of
the measured protein expression xi in each experiment (not
explicitly annotated) from the value which is predicted by the
factor model. As u1..u4, m1,..m3 are binary variables (kinase
inhibitor is administered in the experiment or not), both xi and
ck are functions mapping [0,1]
7 =.R1 for each i and k,
respectively. Because of the small size of the data set, which is
limited by the set of experiments, identifiability of the number of
factors m has been limited. Hence correlations between the
protein expressions in all experiments have been analyzed only in
2 and 3 dimensions restricting m to 3. As we found no significant
increase of model quality at m= 3 compared to m=2 we did not
analyse higher values of m. Moreover, in order to reduce the
dimensionality, the combinations of wt and T351 mutations with
IM, DASA and NILO have been analyzed separately from the
respective combinations with DANU, as we found a high degree of
multi-variate correlations among the proteins in these combina-
tions. Then, in a second step, the deviations induced by T315
mutation and DANU from the model have been analyzed
separately. Although this decomposition of the workflow is not
necessary, it helped to reduce the effective dimensionality and
improving the stability of the respective multivariate correlations
and the respective networks.
The factor model indicates that the network representing the
mechanism contains m critical nodes (the minimal cut of the
network), such that the knock out of these m nodes will be the final
blow for the network (Figure S2B). If the factor-model is correct up
to random noise for all proteins, then the deviations ei will show a
normal distribution. Alternatively, if the MoA involves two (or
more) functional pathways inducing different protein sets each, the
kinase inhibitors can each involve either all the functional
pathways or a set of pathways specific for each drug (Figure
S2C). In the latter case factor analysis will indicate the existence of
at least two independent factors as the distribution of the
deviations ei, will show a non-normal distribution. Hence the
non-normality of the model deviations ei provides a mean for
discrimination between models of type 1b) and 1c). In the latter
case the protein groups have to be classified using regression
clustering methods.
Integration of Protein Expression Data and Apoptosis
Induction
In the second step we assessed the efficiency of the drugs
induced apoptosis compared to the drug induced protein
expression. We aimed to develop a meso scale model describing
only the dominant routes from drug action to both induction of
apoptosis and protein expression as well as their interaction with
mutations. In contrast to the analysis described above, we had to
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integrate heterogeneous readouts, namely apoptosis and protein
expressions into a meso scale model.
To identify the meso scale network which represents the drug
induced protein expressions as well as induction of apoptosis in
Ba/F3-p210-, M351T and -T315I cell lines, we focused the
analysis on the subset of 10 proteins showing differential
expression in all three cell lines.
To establish the model for apoptosis induction, the multi-variate
correlations between the protein expressions have been assessed
using factor analysis, combined with the analysis of the distribu-
tions of the residues. The mechanism of induction of protein
expression and apoptosis by TKIs may differ in detail between the
drugs, although the principal MoA, namely the inhibition of BCR-
ABL, is the same. Hence the data represent a convolution of the
main, common MoA and drug specific mechanisms, which are
hard to reconstruct in a direct, one step approach. Hence we
choose a two-step modeling workflow. In a first step of
approximation, factor analysis was used for the characterization
of the common, dominant mechanism of induction of protein
expression together with apoptosis for all TKIs. As factor analysis
tends to neglect apparent ‘‘outliers’’ in the data, it is superior to
linear models like PLS in order to quantify the main contributions
of the TKIs and the mutations to the dominant mechanism
without mixing drug-specific mechanisms with the common
mechanism.
In a second step the specific properties of the TKIs have been
assessed by analysis of the TKI- and mutation specific deviations
from the dominant factor model identified in the first step. In this
approach the deviations from the model describing the dominant
mechanism are not interpreted as noise. They serve as a filter
which allows to decompose the data with respect to information
induced by an overall dominant mechanism (which is not specific
to the TKI’s) and the information which is induced by
mechanisms specific to the respective TKI.
Supporting Information
Figure S1 A–B: These figures show the concept of
analysis of correlations of drug-induced expression
shifts for large protein sets between wildtype and
mutated cells in order to identify the localisation of the
mutation-induced breakpoint. In (A) the mutation affects the
pathways towards all proteins equally by breaking the pathway
upstream of the first bifurcation node (blue bullet). In contrast, (B)
shows that a breakpoint downstream the first bifurcation node
affects the structure of the correlations of the drug-induced
expression among the set of proteins. Hence analysis of the
structure of correlations reveals infromation with respect to the
localisation of the mutation-induced breakpoint.
(TIF)
Figure S2 A–C: Schematic representation of meso scale
pathways structure. (A) Network structure if no correlations
between the 4 drugs can be found, (B) if critical meso scale nodes
can be described and (C) if different drugs acted on different
nodes.
(TIF)
Table S1 Proteins significantly regulated in Ba/F3-p210
cells. Lists of Proteins that were significantly regulated in each of
the subsets (IM, NILO, DASA and DANU). The relative
expression values compared to the average expression values of
control samples (DMSO) are presented.
(DOC)
Table S2 Proteins significantly regulated in Ba/F3-
M351T cells. Lists of Proteins that were significantly regulated
in each of the subsets (IM, NILO, DASA and DANU). The
relative expression values compared to the average expression
values of control samples (DMSO) are presented.
(DOC)
Table S3 Proteins significantly regulated in Ba/F3-
T315I cells. Lists of Proteins that were significantly regulated
in each of the subsets (IM, NILO, DASA and DANU). The
relative expression values compared to the average expression
values of control samples (DMSO) are presented.
(DOC)
Table S4 Proteins affected by DANU in Ba/F3-p210
cells analyzed by regression clustering.
(DOC)
Acknowledgments
We thank Novartis (Imatinib and Nilotinib), Nerviano Medical Sciences
(Danusertib) and Bristol Myers Script (Dasatinib) for providing the drugs.
The data have been presented 2008 as a talk on the annual meeting of the
American Society of Haematology.
Author Contributions
Conceived and designed the experiments: SB AS THB. Performed the
experiments: SB TW SV CS MB C. Barett AS. Analyzed the data: SB SV
CS HP AS. Wrote the paper: SB GK MB C. Bokemeyer RW AS THB.
References
1. Sebolt-Leopold JS, English JM (2006) Mechanisms of drug inhibition of
signalling molecules. Nature 441: 457–462.
2. Cohen P (2002) Protein kinases [mdash] the major drug targets of the twenty-
first century? Nat Rev Drug Discov 1: 309–315.
3. Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors
for cancer treatment. Nat Rev Drug Discov 2: 296–313.
4. Bain J, McLauchlan H, Elliott M, Cohen P (2003) The specificities of protein
kinase inhibitors: an update. The Biochemical journal 371: 199–204.
5. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008)
A quantitative analysis of kinase inhibitor selectivity. Nat Biotech 26: 127–132.
6. Ross-Macdonald P, de Silva H, Guo Q, Xiao H, Hung C-Y, et al. (2008)
Identification of a nonkinase target mediating cytotoxicity of novel kinase
inhibitors. Molecular Cancer Therapeutics 7: 3490–3498.
7. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, et al. (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors. Nat
Biotech 23: 329–336.
8. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, et al. (2008) Toxicities
associated with the administration of sorafenib, sunitinib, and temsirolimus and
their management in patients with metastatic renal cell carcinoma. European
urology 53: 917–930.
9. Quintas-Cardama A, Cortes JE, Kantarjian H (2008) Practical management of
toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Clinical lymphoma & myeloma 8 Suppl 3: S82–88.
10. Force T, Kolaja KL (2011) Cardiotoxicity of kinase inhibitors: the prediction
and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov
10: 111–126.
11. Al-Lazikani B, Banerji U, Workman P (2012) Combinatorial drug therapy for
cancer in the post-genomic era. Nat Biotechnol 30: 679–692.
12. Pauwels E, Stoven V, Yamanishi Y (2011) Predicting drug side-effect profiles: a
chemical fragment-based approach. BMC Bioinformatics 12: 169.
13. Atias N, Sharan R (2011) An algorithmic framework for predicting side effects of
drugs. J Comput Biol 18: 207–218.
14. Jin G, Fu C, Zhao H, Cui K, Chang J, et al. (2012) A novel method of
transcriptional response analysis to facilitate drug repositioning for cancer
therapy. Cancer research 72: 33–44.
15. McArt DG, Zhang SD (2011) Identification of candidate small-molecule
therapeutics to cancer by gene-signature perturbation in connectivity mapping.
PloS one 6: e16382.
16. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, et al. (2011) Discovery
and preclinical validation of drug indications using compendia of public gene
expression data. Science translational medicine 3: 96ra77.
Meso Scale Networks and Drug Mode-of-Action
PLOS ONE | www.plosone.org 13 January 2013 | Volume 8 | Issue 1 | e53668
17. Fukuzaki M, Seki M, Kashima H, Sese J (2009) Side Effect Prediction Using
Cooperative Pathways. Proceedings of the 2009 IEEE International Conference
on Bioinformatics and Biomedicine: IEEE Computer Society. 142–147.
18. Lehar J, Zimmermann GR, Krueger AS, Molnar RA, Ledell JT, et al. (2007)
Chemical combination effects predict connectivity in biological systems. Mol
Syst Biol 3: 80.
19. Peifer M, Weiss J, Sos ML, Koker M, Heynck S, et al. (2010) Analysis of
compound synergy in high-throughput cellular screens by population-based
lifetime modeling. PloS one 5: e8919.
20. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK (2006) Systems biology and
combination therapy in the quest for clinical efficacy. Nat Chem Biol 2: 458–
466.
21. Zhao XM, Iskar M, Zeller G, Kuhn M, van Noort V, et al. (2011) Prediction of
drug combinations by integrating molecular and pharmacological data. PLoS
Comput Biol 7: e1002323.
22. Gardner TS, di Bernardo D, Lorenz D, Collins JJ (2003) Inferring Genetic
Networks and Identifying Compound Mode of Action via Expression Profiling.
Science 301: 102–105.
23. Xing H, Gardner TS (2006) The mode-of-action by network identification
(MNI) algorithm: a network biology approach for molecular target identification.
Nature protocols 1: 2551–2554.
24. di Bernardo D, Thompson MJ, Gardner TS, Chobot SE, Eastwood EL, et al.
(2005) Chemogenomic profiling on a genome-wide scale using reverse-
engineered gene networks. Nature biotechnology 23: 377–383.
25. Kutalik Z, Beckmann JS, Bergmann S (2008) A modular approach for
integrative analysis of large-scale gene-expression and drug-response data.
Nature biotechnology 26: 531–539.
26. Mitsos A, Melas IN, Siminelakis P, Chairakaki AD, Saez-Rodriguez J, et al.
(2009) Identifying drug effects via pathway alterations using an integer linear
programming optimization formulation on phosphoproteomic data. PLoS
computational biology 5: e1000591.
27. Schuppert A (2011) Efficient reengineering of meso-scale topologies for
functional networks in biomedical applications. Journal of Mathematics in
Industry 1: 6.
28. Fiedler B, Schuppert A (2008) Local identification of scalar hybrid models with
tree structure. IMA Journal of Applied Mathematics 73: 449–476.
29. Schopfer G, Kahrs O, Marquardt W, Warncke M, Mrziglod T, et al. (2005)
Semi-empirical process modelling with integration of commercial modelling
tools; Espun˜a LPaA, editor. Barcelona, Spain. 595–600 p.
30. Schuppert A (1999) Extrapolability of structured hybrid models: A key to the
optimization of complex processes.; Fiedler B, Groeger K, Sprekels J, editors.
Singapore: World Scientific Publishing.
31. Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic
myelogenous leukaemia. Nature reviews Cancer 5: 172–183.
32. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, et al. (2006)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
The New England journal of medicine 355: 2408–2417.
33. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, et al. (2010) Nilotinib
versus imatinib for newly diagnosed chronic myeloid leukemia. The New
England journal of medicine 362: 2251–2259.
34. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, et al. (2010) Dasatinib
versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
The New England journal of medicine 362: 2260–2270.
35. Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, et al.
(2011) Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia
chromosome-positive CML patients with resistance or intolerance to imatinib.
Blood.
36. Keller G, Schafhausen P, Brummendorf TH (2009) Bosutinib: a dual SRC/ABL
kinase inhibitor for the treatment of chronic myeloid leukemia. Expert review of
hematology 2: 489–497.
37. Cortes JE, Kim D-W, Kantarjian HM, Bru¨mmendorf TH, Dyagil I, et al. (2012)
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid
Leukemia: Results From the BELA Trial. Journal of Clinical Oncology.
38. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, et al. (2008)
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small
molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL
mutations including T315I. Blood 111: 4355–4364.
39. Wei G, Rafiyath S, Liu D (2010) First-line treatment for chronic myeloid
leukemia: dasatinib, nilotinib, or imatinib. Journal of hematology & oncology 3:
47.
40. O’Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ (2011) Targeting
the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-
positive leukemia. Clinical cancer research : an official journal of the American
Association for Cancer Research 17: 212–221.
41. O’Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, et al. (2009)
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently
inhibits the T315I mutant and overcomes mutation-based resistance. Cancer cell
16: 401–412.
42. Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, et al. (2007) Crystal
structure of the T315I Abl mutant in complex with the aurora kinases inhibitor
PHA-739358. Cancer research 67: 7987–7990.
43. Winkler DA, Burden FR, Halley JD (2009) Predictive mesoscale network model
of cell fate decisions during C. elegans embryogenesis. Artificial life 15: 411–421.
44. Laubenbacher R, Stigler B (2004) A computational algebra approach to the
reverse engineering of gene regulatory networks. Journal of theoretical biology
229: 523–537.
45. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, et al. (2000)
Functional discovery via a compendium of expression profiles. Cell 102: 109–
126.
46. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The
Connectivity Map: using gene-expression signatures to connect small molecules,
genes, and disease. Science 313: 1929–1935.
47. Nilsson T, Mann M, Aebersold R, Yates JR, 3rd, Bairoch A, et al. (2010) Mass
spectrometry in high-throughput proteomics: ready for the big time. Nature
methods 7: 681–685.
48. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, et al. (2007)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL
kinase inhibitors. Nature biotechnology 25: 1035–1044.
49. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, et al.
(2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib,
nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110:
4055–4063.
50. Breitkopf SB, Oppermann FS, Keri G, Grammel M, Daub H (2010) Proteomics
analysis of cellular imatinib targets and their candidate downstream effectors.
Journal of proteome research 9: 6033–6043.
51. Brehme M, Hantschel O, Colinge J, Kaupe I, Planyavsky M, et al. (2009)
Charting the molecular network of the drug target Bcr-Abl. Proceedings of the
National Academy of Sciences of the United States of America 106: 7414–7419.
52. Balabanov S, Gontarewicz A, Ziegler P, Hartmann U, Kammer W, et al. (2007)
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic
target in BCR-ABL-positive leukemias identified by a proteomics approach.
Blood 109: 1701–1711.
53. Preisinger C, Kolch W (2010) The Bcr-Abl kinase regulates the actin
cytoskeleton via a GADS/Slp-76/Nck1 adaptor protein pathway. Cell Signal
22: 848–856.
54. Guo F, Sigua C, Bali P, George P, Fiskus W, et al. (2005) Mechanistic role of
heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human
acute leukemia cells. Blood 105: 1246–1255.
55. Shiotsu Y, Neckers LM, Wortman I, An WG, Schulte TW, et al. (2000) Novel
oxime derivatives of radicicol induce erythroid differentiation associated with
preferential G(1) phase accumulation against chronic myelogenous leukemia
cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 96: 2284–
2291.
56. Park D, Choi SS, Ha KS (2010) Transglutaminase 2: a multi-functional protein
in multiple subcellular compartments. Amino Acids 39: 619–631.
57. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M,
et al. (2012) Bosutinib is active in chronic phase chronic myeloid leukemia after
imatinib and dasatinib and/or nilotinib therapy failure. Blood 119: 3403–3412.
58. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical
resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or
amplification. Science 293: 876–880.
59. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple
BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine
kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic
myeloid leukemia. Cancer Cell 2: 117–125.
60. Ummanni R, Mundt F, Pospisil H, Venz S, Scharf C, et al. (2011) Identification
of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled
mass spectrometry and systems biology network platform. PloS one 6: e16833.
61. Ummanni R, Barreto F, Venz S, Scharf C, Barett C, et al. (2012) Peroxiredoxins
3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of
prostate cancer cells in vitro. Journal of proteome research 11: 2452–2466.
62. Dyshlovoy SA, Naeth I, Venz S, Preukschas M, Sievert H, et al. (2012)
Proteomic profiling of germ cell cancer cells treated with aaptamine, a marine
alkaloid with antiproliferative activity. J Proteome Res 11: 2316–2330.
63. Preukschas M, Hagel C, Schulte A, Weber K, Lamszus K, et al. (2012)
Expression of Eukaryotic Initiation Factor 5A and Hypusine Forming Enzymes
in Glioblastoma Patient Samples: Implications for New Targeted Therapies.
PloS one 7: e43468.
Meso Scale Networks and Drug Mode-of-Action
PLOS ONE | www.plosone.org 14 January 2013 | Volume 8 | Issue 1 | e53668
